Computer Prompts Could Reduce Empiric Antibiotic Use for UTI
By Elana Gotkine HealthDay Reporter
FRIDAY, April 19, 2024 -- For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts providing patient- and pathogen-specific multidrug-resistant organism (MDRO) risk estimates can reduce empiric extended-spectrum antibiotic use, according to a study published online April 19 in the Journal of the American Medical Association.
Shruti K. Gohil, M.D., M.P.H., from the University of California Irvine School of Medicine, and colleagues examined whether CPOE prompts providing patient- and pathogen-specific MDRO risk estimates could reduce use of empiric extended-spectrum antibiotics for treatment of UTI in a cluster-randomized trial in 59 U.S. community hospitals. The effect of a CPOE stewardship bundle versus routine stewardship (29 and 30 hospitals, respectively) on antibiotic selection during the first three hospital days in noncritically ill adults hospitalized with UTI was compared for a 15-month intervention period and an 18-month baseline period. Participants had low estimated absolute risk for MDRO UTI.
Data were included for 127,403 adults: 71,991 at baseline and 55,412 during the intervention periods. The researchers observed a 17.4 percent reduction in empiric extended-spectrum days of therapy in the group using CPOE prompts compared with routine stewardship (rate ratio, 0.83). No significant difference was seen between the CPOE prompt and routine groups in terms of the safety outcomes of mean days to intensive care unit transfer and hospital length of stay.
"This intervention could be a viable strategy to reduce extended-spectrum antibiotics in up to 200,000 adults hospitalized in the U.S. who receive unnecessarily broad antibiotics for UTI annually," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
FDA Approves New Antibiotic, Pivya, for Uncomplicated Urinary Tract Infections
TUESDAY, April 30, 2024 -- The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract...
Obstructive Sleep Apnea Linked to Bladder Pain/Interstitial Cystitis
THURSDAY, March 7, 2024 -- Obstructive sleep apnea (OSA) seems to be associated with bladder pain syndrome/interstitial cystitis (BPS/IC) in women, according to a study published...
Cefepime-Taniborbactam Superior to Meropenem for Complicated UTI
THURSDAY, Feb. 15, 2024 -- For adults with complicated urinary tract infection (UTI), including acute pyelonephritis, cefepime-taniborbactam is superior to meropenem, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.